Metatastic Breast Cancer - New Dosing Schedule Suggests Potential Amplified Clinical Activity Of Novel KSP Inhibitor
Cytokinetics, Incorporated (NASDAQ: CYTK) announced that a poster presentation summarizing interim data from the Phase I portion of a Phase I/II clinical trial evaluating ispinesib, a novel inhibitor of kinesin spindle protein (KSP), in patients with locally advanced or metastatic breast cancer was presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) held from May 29 - June 2, 2009 in Orlando, FL.
More: continued here
Filed under: Breast Cancer on June 21st, 2009
You must be logged in to post a comment.